Evgen Pharma Share Discussion Threads

[carlisle44] 14/2/2021 15:09

Nobby I would be glad to join your Guild. Can you please assist with a coin?

[supernumerary] 14/2/2021 14:46

Nobby - a coin and invite would be much appreciated. TIA

[moneymunch] 14/2/2021 14:21

There are currently over 25,000 patients in hospital and although the R numbers are dropping because of the lockdown, cases are still high and no doubt would increase again if and when the lockdown is relaxed , we also know that SFX-01's Covid recruitment process is now rapid, 9 patients as of 7/12/20, 56 patients as of 18/1/21 and 89 patients confirmed 1/2/21, and Prof Chalmers has also put the call out 19/1/21 for more trial sites to participate, whether or not this will include any international sites given his strong international network with other academics involved in respiratory desease, is yet to be seen.

We also know that SFX-01's recruitment isn't reliant on paitients testing Covid positive, as it is focused on ARDS, a condition with very few effective treatments, and so no shortage of potential patients for SFX-01's recruitment over the next few months or so imho, during which time we could have multiple positive newsflow from the rest of the pipeline which could drive Evgen's share price to new highs. Exciting times for all invested with undoubted transformational UPside potential, with c£13m cash in the bank and a market cap of c£20m at a share price of 8p by first week of March...Fill ya Boots!!! Gla holders ;-)

...................

There are about 200,000 cases of ARDS each year in the United States. ARDS is a serious disease. The chances of dying from this disease are around 30% to 50%. Those who survive will often have long hospital stays.



...................

The Telegraph

R number drops below 1 for first time since July


12 February 2021 • 6:59pm


The reproduction number, or R value, of coronavirus has fallen below one for the first time since July and is now estimated to be between 0.7 and 0.9 across the UK.

In a sign that lockdown restrictions are having an impact and the epidemic is shrinking, scientists advising the Government gave their most optimistic outlook for the R number since cases fell last summer.

It comes as new data from the Office for National Statistics shows a drop in infections, with around one in 80 people in private households in England having Covid-19 between January 31 and February 6, the equivalent of 695,400 people.

This is down from around one in 65 people for the period January 24 to 30.

On February 9, the latest date for which figures are available, the number of patients in hospital with Covid-19 in the UK stood at 25,621.

But while scientists advising the Government believe cases of Covid-19 are dropping at a decent pace across England, they have warned that infection levels remain high.

Kevin McConway, Emeritus Professor of Applied Statistic from The Open University, said: “These revisions of the ranges for R and the growth rate are more good news, on top of the good news from the ONS Infection Survey earlier today."

"But that doesn’t mean we can take the foot off the brake yet."

..................

19/1/21

James D Chalmers

@ProfJDChalmers


STAR-COVID is still looking for additional trial sites. Anyone interested please e-mail or direct message me.

.....................

11/11/20

Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."

[moneymunch] 14/2/2021 14:05

Extremely encouraging that Prof Chalmers has joined Evgen's Scientific Advisory Board, and very interesting at this stage of proceedings that the following research by Prof Dinkova-Kostova, who also is a Scientic advisor to Evgen and one of the lead investigators on SFX-01's Covid/ARDS trial and has a lifes work focused on NRF2 and all things Sulforaphane, was also included in the newly released Evgen Investor Presentation...all bodes well imho. Gla :')



.....

Can Activation of NRF2 Be a Strategy against COVID-19?

AntonioCuadrado

Albena T.Dinkova-Kostova

Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19.

[moneymunch] 14/2/2021 13:55

The Gmome is short to 8p....Fill ya Boots!!! ;-)

[nobbygnome] 14/2/2021 13:53

And just to say I will be posting later today on the Guild thread precisely why I think SFX-01 has little chance of working in SARS and why it didn't work in the SAH trial. However, I stress I think it stands a good chance of working in oncology inidications and other indications such as ME.

[moneymunch] 14/2/2021 13:31

No begging or grovelling for coins required.

A new thread for all......Gla ;-)

[nobbygnome] 14/2/2021 13:30

Just to reiterate the Guild is open to everyone. No-one will be excluded but once in you have to abide by the rules!

[moneymunch] 14/2/2021 13:11

Evgen will have c£13m cash in the bank 1st week of March with a market cap of c£20m at 8p a share, with multiple shots on multiple targets, all of which could provide incredible upside on success, and there could be a flurry of positive newsflow across the pipeline in the coming weeks ahead to drive the share price to new highs, not to mention disclosure of the new high quality investors who are participating in Evgen's placing.......Evgen could be the Star share of 2021 as good news rolls in. Gla Holders ;-)

[moneymunch] 14/2/2021 13:06

Commenting on the Fundraising, Huw Jones, CEO of Evgen Pharma plc, said:

"This heavily oversubscribed fundraising is transformative for us and allows us to accelerate both our future clinical and current pre-clinical work dramatically, together with expanding our senior management team to support our growth. We are very pleased with recent progress of our work on SFX-01 and are most grateful for the support shown in this placing by existing shareholders. The Placing also brings a number of new, high quality shareholders to our register and we offer a warm welcome to them as we accelerate our progress in a range of cancers and acute respiratory distress."

[moneymunch] 14/2/2021 12:52

A new thread for all......Gla ;-)

[moneymunch] 14/2/2021 12:50

This my first thread and so a work in progress, all welcome. Gla ;-)

[moneymunch] 14/2/2021 12:45

!FOLLOWFEED
Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation. Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology. We are also researching a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to turn this scientific promise into commercially successful products, addressing important clinical needs.

Our clinical pipeline is derived from our proprietary Sulforadex® platform technology; a means of synthesising and concurrently stabilising sulforaphane-based compounds in a solid dose form. Lead product, SFX-01, has produced positive results in an open-label Phase II trial in patients with ER+ metastatic breast cancer that had previously become resistant to all prior hormone therapies.

The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.

.......................

Evgen Pharma Website



.......................

Evgen Pharma PLC

13 July 2021

During the last few months we have made significant progress in our glioblastoma ('GBM') development programme, building on exciting initial data from the University L'Aquila which demonstrated tumour shrinkage and significantly extended survival times in in vivo models of GBM. Further work at The University of Auckland and with a Clinical Research Organisation has substantiated and expanded upon important elements of these data, and we are well-advanced in generating a pre-clinical data package that would justify moving into a Phase II clinical trial. We currently project such a trial commencing in the first half of 2022. In parallel with this activity, we have applied for Orphan Drug status for SFX-01 in GBM from the US Food and Drug Administration (FDA) and we are compiling an Investigational New Drug application to be submitted to the FDA later this year.

As announced earlier today, we are pleased to report preliminary in vitro data showing the significant reduction of cell proliferation and increased apoptosis (cell death) of Juvenile Myelomonocytic Leukaemia stem cells in the presence of SFX-01, compared to normal controls. The study also showed that SFX-01 significantly impacted cell proliferation and increased cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell line. The data were generated by Dr Eleni Louka and Professor Adam Mead of the MRC Weatherall Institute of Molecular Medicine at Oxford University. We are investigating options for building on this data with potential scientific partners.

Last month we were pleased to report that our collaborators at the Manchester Breast Centre, the University of Manchester, are conducting further in vitro preclinical work to assess the impact of SFX--01 in CDK4/6 resistance models. An increasing body of data from there shows that in these models SFX--01 may suppress tumour growth and metastasis in patients who have become resistant to CDK4/6 inhibitors (palbociclib, Ibrance, Pfizer). In particular, SFX--01 reduced the viability and mammosphere colony formation ability of palbociclib--resistant cells in vitro.

In summary, the Company is well funded to execute pre-clinical and/or clinical programmes in oncology and looks forward to updating the market on these programmes in due course.

An updated presentation on the Company is available on at: under 'Latest AGM Presentation'.

....................................

21st July 2021

Evgen Pharma PLC's (LON:EVG) Dr Huw Jones joins Proactive London to go through their portfolio with progress for is lead asset on two fronts in the field of cancer.

Evgen portfolio update on core field of cancer, 'the R&D is entirely on plan and on budget'



...................................

2/9/21

Evgen Pharma PLC Glioma Orphan Drug designation granted by FDA

Dr Huw Jones, CEO of Evgen, commented: "We are delighted that our team and advisors have successfully gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering."

............................

10/11/21

The in vitro data, in GBM cells and patient-derived glioma-initiating cells, show anti-tumour activity of the Company's lead asset SFX-01. The work goes on to show in vivo anti-tumour activity in both sub-cutaneous and orthotopic xenograft (tumour cell lines are implanted in the brain) models of GBM. In both models, SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved survival. The in vitro work was complemented by a recent pre-print publication from a different laboratory, the University of Auckland, New Zealand, in patient derived cells and 3D spheroid models of GBM (Leung et al 2021).

Evgen recently announced the grant of Orphan Drug Designation in the USA for Malignant Glioma, affording the programme additional data protection and other incentives.

Dr Huw Jones, CEO of Evgen, commented: "We are very pleased to see the publication of this important work by Dr Festuccia and colleagues. The data generated underpin our decision to focus on glioblastoma as one of our core programmes. Our design work on a Phase 2 study in glioblastoma patients is well advanced and we are discussing the design with a number of prominent UK and European clinical centres. In due course we hope to contribute a new treatment option for patients with this devastating disease."

....................

Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.

5. Conclusions

In this work, we used in vitro and in vivo experimental models to assess the therapeutic potential of SFX-01 for GBM treatment. Our data suggest that SFN targets ER stress and NRF2, paying as a “master regulator” of the body’s stress response. Secondary but very important effects are the inhibition of HDAC activity especially on class I HDACs and inhibition of STAT3 with reduced activity of NFKB pathways which modulate progression of GBM and induce ROS. So, metabolic, oxidative, and epigenetic modifications are the bases of the different effects of SFN. Our study provided detailed evidence that SFX-01 induced cell death and inhibited the growth of GBM cells and xenografts through the modulation of multiple cell-signaling pathways, demonstrating its potential as a new compound for GBM treatment. SFX-01 was also highly effective in eliminating GSCs through the induction of cell differentiation, compared to the less-malignant astrocyte phenotype. SFX-01 also reduced the vasculogenic properties of GBM cells, thus inhibiting the growth of GBM xenografts in vivo. SFX-01 triggered DNA damage and increased RT-mediated γ-H2Ax expression through the production of ROS. Overall, our preclinical data indicated that the effects of SFX-01 are due to multiple molecular mechanisms, participating in switching off autophagy and switching on apoptosis, which are responsible for SFX-01-mediated cell death.

[quattro44] 14/2/2021 12:43

>> Nobbygnome. Would appreciate a coin if poss please. Hopefully turn out to be as good as Sng guild!

[njb67] 14/2/2021 12:26

ng
can you send me a coin too pls

[fanramptastic mate] 14/2/2021 11:50

>>>nobby

cap held out 'spare a coin or two guv'

TIA

[moneymunch] 14/2/2021 11:44

ps timbo, fair enough that you're going to set up a secret squirrel thread with the sanctimonious Gnome, but why dismantle this one and remove the charts here, especially when you have other threads where perhaps you've moved on , but left the charts etc in place???

[harrythehorse] 14/2/2021 11:39

Hi Nobby, can you let me in please, i very much value your Synairgen guild/

thanks

[moneymunch] 14/2/2021 11:36

ps and the main culprit and antagonist of the majority of the bickering is Nobbygnome who rates SFX-01's chances for Covid/Ards at zero....Gl ;-)